Middle East And Africa Malaria Treatment Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2022 –2029 |
 Tamanho do mercado (ano base ) | USD 1,716.98 Million |
 Tamanho do mercado ( Ano de previsão) | USD 2,884.56 Million |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado de tratamento da malária no Médio Oriente e África, por agente (Plasmodium Falciparum, P. Vivax, P. Ovale, P. Malariae, P. Knowlelsi), classe de medicamentos (compostos de aril aminoálcool, compostos antifolatos, compostos de artemisinina, outros), tipo de medicamento ( De marca, genéricos), tratamento (medicamentos antimaláricos, outros), diagnóstico (diagnóstico rápido, microscopia, testes de diagnóstico molecular), via de administração (oral, parenteral, outros), faixa etária (pediátrico, adulto, geriátrico), forma farmacêutica ( comprimido , Injecção, Outros), Utilizadores Finais (Hospitais, Clínicas Especializadas, Homecare, Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online, Outros) - Tendências do Sector e Previsão para 2029
Análise e dimensão do mercado
De acordo com a Organização Mundial de Saúde (OMS), ocorreram cerca de 241 milhões de casos de malária em todo o mundo em 2020. A malária é transmitida através da picada de uma fêmea do mosquito Anopheles, portadora do parasita Plasmodium. Febre, cansaço, náuseas e dor de cabeça são sintomas frequentes. O tipo de Plasmodium causador da malária e a área geográfica onde a doença foi adquirida determinam as opções de tratamento. Além disso, as mulheres grávidas e lactantes, bem como as crianças pequenas, necessitam de atenção específica. A cloroquina é comummente utilizada para tratar doentes com malária; no entanto, nos casos de resistência à cloroquina, são empregues diferentes medicamentos.
A Data Bridge Market Research analisa que o mercado de tratamento da malária no Médio Oriente e África foi avaliado em 1.716,98 milhões de dólares em 2021 e deverá atingir os 2.884,56 milhões de dólares até 2029, registando um CAGR de 6,70% durante o período de previsão de 2022 a 2029. Além disso aos insights de mercado, tais como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de investigação de mercado da Data Bridge inclui também análise especializada aprofundada, epidemiologia do paciente, análise de pipeline, análise de preços e estrutura regulamentar.
Âmbito do relatório e segmentação de mercado
|
Métrica de relatório |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (personalizável para 2014 - 2019) |
|
Unidades Quantitativas |
Receita em milhões de dólares, volumes em unidades, preços em dólares |
|
Segmentos cobertos |
Agente (Plasmodium Falciparum, P. Vivax, P. Ovale, P. Malariae, P. Knowlelsi), Classe de Medicamentos (Compostos de Aril Aminoálcool, Compostos Antifolatos, Compostos de Artemisinina, Outros), Tipo de Medicamento (de Marca, Genéricos) , Tratamento (Medicamentos Antimaláricos) , Outros), Diagnóstico (Diagnóstico Rápido, Microscopia, Testes de Diagnóstico Molecular), Via de Administração (Oral, Parentérica, Outros), Faixa Etária (Pediátrico, Adulto, Geriátrico), Forma Posológica (Comprimido, Injetável , Outros), Utilizadores Finais (Hospitais, Clínicas Especializadas, Homecare, Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online, Outros) |
|
Países abrangidos |
Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Israel, Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA). |
|
Participantes do mercado abrangidos |
Actiza Pharmaceutical Private Limited (India), AdvaCare Pharma (US), Ipca Laboratories Ltd. (India), Bliss GVS Pharma Ltd. (India), GeoVax (US), Sumaya Biotech (Germany), VLP Therapeutics (US), OSIVAX (France), AJANTA PHARMA (India), Strides Pharma Science Limited (India), Mylan N.V. (US), Zydus Cadila (India), Cipla Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), Hikma Pharmaceuticals PLC (UK), Amneal Pharmaceuticals LLC. (US), Taj Pharmaceuticals Limited. (India), Lupin (India), Novartis AG (Switzerland) |
|
Market Opportunities |
|
Market Definition
Malaria is a fever illness caused by Plasmodium parasites that are transmitted to humans by mosquito bites from infected female Anopheles mosquitos. Malaria is usually treated with a single medicine as a first line of treatment, and combination drug therapy is used as a second line of treatment. Antimalarial medications are available in tablet, injectable, and capsule form. For the treatment of malarial infection, several medications such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others are available in the market.
Middle East and Africa Malaria Treatment Market Dynamics
Drivers
- Rise in the prevalence of malaria in low-income countries
The rise in prevalence of malaria in low-income countries is anticipated to flourish the growth rate of the market. Malaria is a life-threatening infectious disease spread by female Anopheles mosquitoes and caused by the Plasmodium parasite. The malaria epidemic is spreading, and climate change is making it easier for mosquito vectors to thrive. According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America. In addition, malaria is most common in Africa, Southeast Asia, the Eastern Mediterranean, and the Western Pacific.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of malaria treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the malaria treatment market. Additionally, surging number of geriatric population and rising use of insect repellent among people will result in the expansion of malaria treatment market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the malaria treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the malaria treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the treatment is anticipated to obstruct the market’s growth rate. The lack of healthcare infrastructure in developing economies and strict regulatory process will challenge the malaria treatment market. Additionally, complications involved with malaria such as low blood sugar, anemia, organ failure, breathing problems, and cerebral malaria will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Middle East and Africa malaria treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa malaria treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Malaria is prevalent in hot, humid tropical settings. Every year, 2,000 people in the United States contract malaria. Malaria affects around 220 million people worldwide every year. In Africa and South Asia, the bulk of these occurrences occur. Every year, over 450,000 people suffer from the disease.
Middle East and Africa malaria treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Middle East and Africa Malaria Treatment Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. One of the major causes driving the expansion of the antimalarial medicine industry is the exponential increase in COVID-19 cases around the world. According to the World Health Organization's most recent data, there were around 1.8 million confirmed cases of coronavirus illness worldwide. Chloroquines can prevent the virus from infecting individuals because they can affect the pH at the cell surface. As a result, it is believed that hydroxychloroquine pills will block the virus that causes COVID-19. With an increase in COVID-19 infections around the world and hydroxychloroquine as a viable treatment, demand for antimalarial medications to combat the coronavirus may rise.
Recent Development
- In March 2021, Amivas (US), LLC had announces the U.S. launch of Artesunate for injection use for initial treatment of severe malaria. Artesunate for Injection was approved by the United States Food and Drug Administration (FDA) on May 26, 2020 for the treatment of severe malaria in adults and children. Amivas, based in Frederick, Maryland, has added Artesunate for Injection to its commercial portfolio as the company's first FDA-approved medication.
Middle East and Africa Malaria Treatment Market Scope
The Middle East and Africa malaria treatment market is segmented on the basis of diagnosis, agent, treatment, drug class, dosage form, drug type, route of administration, age group, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Agent
- Plasmodium Falciparum
- P. Vivax
- P. Ovale
- P. Malariae
- P. Knowlelsi
Treatment
- Antimalarial Drugs
- Artemisinin-based combination therapies (ACTs)
- Chloroquine phosphate
- Atovaquone-proguanil
- Primaquine phosphate
- Others
- Others
Drug class
- Aryl Aminoalcohol Compounds
- Antifolate Compounds
- Artemisinin Compounds
- Others
Drug Type
- Branded
- Generics
Diagnosis
- Rapid Diagnostics
- Microscopy
- Molecular Diagnostic Tests
Route of Administration
- Oral
- Parenteral
- Others
Dosage Form
- Injection
- Tablet
- Others
Age Group
- Pediatric
- Adult
- Geriatric
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Middle East and Africa Malaria Treatment Market Regional Analysis/Insights
The Middle East and Africa malaria treatment market is analysed and market size insights and trends are provided by country, diagnosis, agent, treatment, drug class, dosage form, drug type, route of administration, age group, end-users and distribution channel as referenced above.
Os países abrangidos pelo relatório de mercado de tratamento da malária no Médio Oriente e África são a Arábia Saudita, os Emirados Árabes Unidos, a África do Sul, o Egito, Israel, o Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA ).
Prevê-se que a Arábia Saudita cresça a uma taxa de crescimento substancial durante o período de previsão de 2022-2029 devido ao aumento da sensibilização para o tratamento da malária e ao aumento do nível de investimento por parte dos participantes do mercado nesta região.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas do Médio Oriente e de África e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se proporciona uma análise de previsão dos dados do país.
Cenário competitivo e análise da quota de mercado no tratamento da malária no Médio Oriente e África
O panorama competitivo do mercado de tratamento da malária no Médio Oriente e em África fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença no Médio Oriente e em África, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, largura do produto e amplitude, domínio de aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de tratamento da malária no Médio Oriente e em África.
Alguns dos principais players que operam no mercado do tratamento da malária no Médio Oriente e em África são:
- Actiza Pharmaceutical Private Limited (Índia)
- AdvaCare Pharma (EUA)
- Ipca Laboratories Ltd. (Índia)
- Bliss GVS Pharma Ltd. (Índia)
- GeoVax (EUA)
- Sumaya Biotech (Alemanha)
- Terapêutica VLP (EUA)
- OSIVAX (França)
- AJANTA PHARMA (Índia)
- Strides Pharma Science Limited (Índia)
- Mylan NV (EUA)
- Zydus Cadila (Índia)
- (EUA)
- Sun Pharmaceutical Industries Ltd. (Índia)
- Sanofi (França)
- Hikma Pharmaceuticals PLC (Reino Unido)
- Amneal Farmacêutica LLC. (NÓS)
- Taj Farmacêutica, Lda. (Índia)
- Lupin (Índia)
- Novartis AG (Suíça)
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET TYPE COVERAGE GRID
2.8 AGENT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
5.1 LIST OF PIPELINE PRODUCTS
6 REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN GOVERNMENT INITIATION AND EXPENDITURE FOR PREVENTION OF MALARIA
7.1.2 HIGH PREVALENCE AND DISEASE BURDEN OF MALARIA
7.1.3 RISE IN MEDICAL INSURANCE
7.1.4 HUMID CLIMATIC CONDITIONS AND EFFICIENT MOSQUITO (ANOPHELES GAMBIAE COMPLEX) IN CERTAIN PARTS OF AFRICA
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH ANTI-MALARIA DRUGS
7.2.2 LACK OF AWARENESS RELATED TO SYMPTOMS OF MALARIA
7.2.3 LOW ECONOMIC GROWTH, UNDERDEVELOPED HEALTHCARE INFRASTRUCTURE, AND LACK OF ACCESS TO ADVANCED TREATMENT
7.3 OPPORTUNITY
7.3.1 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
7.3.2 RISING PRODUCT LAUNCHES
7.3.3 INCREASE IN THE PRODUCTION AND EXPORT AS WELL AS IMPORT OF HYDROXYCHLOROQUINE AND CHLOROQUINE
7.4 CHALLENGES
7.4.1 REGULATORY CHALLENGES TO ANTIMALARIAL DRUG APPROVAL
7.4.2 ACHIEVING UNIVERSAL ACCESS
8 COVID-19 IMPACT ON MALARIA TREATMENT IN HEALTHCARE INDUSTRY
8.1 PRICE IMPACT
8.2 IMPACT ON SUPPLY CHAIN
8.3 IMPACT ON DEMAND
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY AGENT
9.1 OVERVIEW
9.2 PLASMODIUM FALCIPARUM
9.3 P. VIVAX
9.4 P. OVALE
9.5 P. MALARIAE
9.6 P. KNOWLELSI
10 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 CHLOROQUINE
10.2.2 PRIMAQUINE
10.2.3 ARTEMISININ-BASED COMBINATION THERAPY (ACT)
10.2.3.1 ARTEMETHER–LUMEFANTRINE
10.2.3.2 ARTESUNATE-AMODIAQUINE
10.2.3.3 DIHYDROARTEMISININ-PIPERAQUINE
10.2.3.4 OTHERS
10.2.4 QUININE
10.2.5 HYDROXYCHLOROQUINE
10.2.6 MEFLOQUINE
10.2.7 NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS)
10.2.7.1 SULFADOXINE-PYRIMETHAMINE WITH CHLOROQUINE
10.2.7.2 SULFADOXINE-PYRIMETHAMINE WITH AMODIAQUINE
10.2.7.3 OTHERS
10.2.8 OTHERS
10.3 VACCINE
10.3.1 RTS,S/AS01
10.3.2 PFSPZ
10.3.3 OTHERS
11 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 SUPPRESSIVE TREATMENT
11.3 RADICAL TREATMENT
12 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
12.3.1 ARTEFAN
12.3.2 COARTEM
12.3.3 RIAMET
12.3.4 MALARONE
12.3.5 EURARTESIM
12.3.6 LONART
12.3.7 OTHERS
13 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 INTRAMUSCULAR
13.3.3 SUBCUTANEOUS
14 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACIES
15.4 RETAIL PHARMACIES
15.5 ONLINE PHARMACIES
16 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY GEOGRAPHY
16.1 MIDDLE EAST & AFRICA
16.1.1 NIGERIA
16.1.2 DEMOCRATIC REPUBLIC OF THE CONGO
16.1.3 UGANDA
16.1.4 MOZAMBIQUE
16.1.5 NIGER
16.1.6 CÔTE D’IVOIRE
16.1.7 SOUTH AFRICA
16.1.8 SAUDI ARABIA
16.1.9 UAE
16.1.10 ISRAEL
16.1.11 EGYPT
16.1.12 KUWAIT
16.1.13 REST OF MIDDLE EAST & AFRICA
17 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 AJANTA PHARMA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 NOVARTIS AG
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 CIPLA INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 STRIDES PHARMA SCIENCE LIMITED
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 HIKMA PHARMACEUTICALS PLC
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 IPCA LABORATORIES LTD.
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 MYLAN N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 ACTIZA PHARMACEUTICAL PRIVATE LIMITED
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 ADVACARE PHARMA
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 AMNEAL PHARMACEUTICALS LLC
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 BLISS GVS PHARMA LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 GEOVAX
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MMV
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 OSIVAX
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SUMAYA BIOTECH
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 TAJ PHARMACEUTICALS LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 VLP THERAPEUTICS
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 ZYDUS CADILA
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 3 ESTIMATED MALARIA CASES AND DEATHS BY REGION, 2018
TABLE 4 FUTURE VECTOR CARE - FUTURE GENERALI (MALARIA CARE FAMILY HEALTH PLAN)
TABLE 5 REGULATORY CHALLENGES TO ANTIMALARIAL DRUG APPROVAL.
TABLE 6 CHALLENGES AND PROBLEMS THAT DRIVE THE R&D FRAMEWORK
TABLE 7 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY AGENT 2019-2027 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA PLASMODIUM FALCIPARUM IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA P. VIVAX IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA P. OVALE IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA P. MALARIAE IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA P. KNOWLELSI IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TYPE 2019-2027 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA VACCINE IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE 2019-2027 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA SUPPRESSIVE TREATMENT IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA RADICAL TREATMENT IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE 2019-2027 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA GENERICS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA ORAL IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY END USER 2019-2027 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA HOSPITALS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2027 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA DIRECT TENDER IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 41 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 42 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 43 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 44 MIDDLE EAST & AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 45 MIDDLE EAST & AFRICA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 46 MIDDLE EAST & AFRICA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 47 MIDDLE EAST & AFRICA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 48 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 49 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 50 MIDDLE EAST & AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 51 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 52 MIDDLE EAST & AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 53 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 54 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 55 NIGERIA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 56 NIGERIA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 57 NIGERIA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 58 NIGERIA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 59 NIGERIA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 60 NIGERIA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 61 NIGERIA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 62 NIGERIA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 63 NIGERIA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 64 NIGERIA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 65 NIGERIA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 66 NIGERIA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 67 NIGERIA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 68 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 69 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 70 DEMOCRATIC REPUBLIC OF THE CONGO MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 71 DEMOCRATIC REPUBLIC OF THE CONGO ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 72 DEMOCRATIC REPUBLIC OF THE CONGO NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 73 DEMOCRATIC REPUBLIC OF THE CONGO VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 74 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 75 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 76 DEMOCRATIC REPUBLIC OF THE CONGO BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 77 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 78 DEMOCRATIC REPUBLIC OF THE CONGO PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 79 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 80 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 81 UGANDA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 82 UGANDA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 83 UGANDA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 84 UGANDA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 85 UGANDA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 86 UGANDA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 87 UGANDA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 88 UGANDA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 89 UGANDA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 90 UGANDA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 91 UGANDA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 92 UGANDA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 93 UGANDA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 94 MOZAMBIQUE MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 95 MOZAMBIQUE MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 96 MOZAMBIQUE MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 97 MOZAMBIQUE ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 98 MOZAMBIQUE NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 99 MOZAMBIQUE VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 100 MOZAMBIQUE MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 101 MOZAMBIQUE MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 102 MOZAMBIQUE BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 103 MOZAMBIQUE MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 104 MOZAMBIQUE PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 105 MOZAMBIQUE MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 106 MOZAMBIQUE MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 107 NIGER MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 108 NIGER MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 109 NIGER MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 110 NIGER ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 111 NIGER NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 112 NIGER VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 113 NIGER MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 114 NIGER MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 115 NIGER BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 116 NIGER MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 117 NIGER PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 118 NIGER MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 119 NIGER MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 120 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 121 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 122 CÔTE D’IVOIRE MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 123 CÔTE D’IVOIRE ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 124 CÔTE D’IVOIRE NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 125 CÔTE D’IVOIRE VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 126 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 127 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 128 CÔTE D’IVOIRE BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 129 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 130 CÔTE D’IVOIRE PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 131 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 132 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 133 SOUTH AFRICA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 134 SOUTH AFRICA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 135 SOUTH AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 136 SOUTH AFRICA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 137 SOUTH AFRICA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 138 SOUTH AFRICA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 139 SOUTH AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 140 SOUTH AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 141 SOUTH AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 142 SOUTH AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 143 SOUTH AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 144 SOUTH AFRICA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 145 SOUTH AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 146 SAUDI ARABIA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 147 SAUDI ARABIA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 148 SAUDI ARABIA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 149 SAUDI ARABIA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 150 SAUDI ARABIA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 151 SAUDI ARABIA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 152 SAUDI ARABIA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 153 SAUDI ARABIA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 154 SAUDI ARABIA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 155 SAUDI ARABIA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 156 SAUDI ARABIA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 157 SAUDI ARABIA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 158 SAUDI ARABIA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 159 UAE MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 160 UAE MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 161 UAE MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 162 UAE ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 163 UAE NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 164 UAE VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 165 UAE MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 166 UAE MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 167 UAE BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 168 UAE MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 169 UAE PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 170 UAE MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 171 UAE MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 172 ISRAEL MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 173 ISRAEL MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 174 ISRAEL MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 175 ISRAEL ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 176 ISRAEL NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 177 ISRAEL VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 178 ISRAEL MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 179 ISRAEL MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 180 ISRAEL BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 181 ISRAEL MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 182 ISRAEL PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 183 ISRAEL MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 184 ISRAEL MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 185 EGYPT MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 186 EGYPT MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 187 EGYPT MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 188 EGYPT ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 189 EGYPT NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 190 EGYPT VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 191 EGYPT MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 192 EGYPT MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 193 EGYPT BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 194 EGYPT MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 195 EGYPT PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 196 EGYPT MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 197 EGYPT MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 198 KUWAIT MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 199 KUWAIT MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 200 KUWAIT MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 201 KUWAIT ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 202 KUWAIT NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 203 KUWAIT VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 204 KUWAIT MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 205 KUWAIT MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 206 KUWAIT BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 207 KUWAIT MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 208 KUWAIT PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 209 KUWAIT MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 210 KUWAIT MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 211 REST OF MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
Lista de Figura
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: MARKET TYPE COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASE IN GOVERNMENT INITIATION AND EXPENDITURE FOR PREVENTION OF MALARIA IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET
FIGURE 14 THE U.S. FUNDING FOR MIDDLE EAST AND AFRICA MALARIA, FY 2001 –2021
FIGURE 15 MALARIA CASES IN THE 10 HIGHEST BURDEN COUNTRIES IN AFRICA, 2010-2017
FIGURE 16 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, 2019
FIGURE 17 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, 2019-2027 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, CAGR (2020-2027)
FIGURE 19 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, 2019
FIGURE 21 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, 2019-2027 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 23 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, 2019
FIGURE 25 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, 2019-2027 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2020-2027)
FIGURE 27 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, 2019
FIGURE 29 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, 2019-2027 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 31 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 33 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 35 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, 2019
FIGURE 37 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, 2019-2027 (USD THOUSAND)
FIGURE 38 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 39 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 41 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
FIGURE 42 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 43 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 45 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 46 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 47 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 48 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 49 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: COMPANY SHARE 2019 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
